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1. Introduction 
NKG2D (natural-killer group 2, member D) belongs to a sub-family of C type lectin-like 
receptors. NKG2D is a homodimeric, type II transmembrane glycoprotein (Wolan et al., 
2001). The NKG2D gene is located in the NK gene complex which is on chromosome 6 in the 
mouse (Ho et al., 1998) and chromosome 12 in human (Glienke et al., 1998). Like most 
activating receptors, NKG2D is a multi-subunit receptor complex. Signaling in NKG2D is 
mediated by specialized signaling adaptors. In mouse NKG2D associates with two distinct 
adaptors: DAP-10 and DAP-12/KARAP (Diefenbach et al., 2002a), while in human NKG2D 
exclusively uses DAP-10 (Rosen et al., 2004). Non-covalent interactions are responsible for 
these associations (Diefenbach et al., 2002b). One NKG2D homodimer associates with two 
DAP-10 dimers to form a hexameric complex (Garrity et al., 2005). Two distinct NKG2D 
isoforms (NKG2D-S and NKG2D-L) are expressed in mouse as a result of alternative exon 
usage and are responsible for differential adaptor associations. The short (NKG2D-S) and 
long (NKG2D-L) isoforms differ by their 13 NH2-terminal amino acids. While DAP-10 
associates with both NKG2D isoforms, the extended cytoplasmic domain of NKG2D-L 
prevents the association with DAP-12 (Diefenbach et al., 2002a; Rosen et al., 2004). NKG2D-
L is constitutively expressed in resting NK cells. In contrast, the abundance of NKG2D-S 
increases considerably upon NK cell stimulation with cytokines (Rabinovich et al., 2006).  
NKG2D has the ability to interact with a significant number of distinct ligands with 
affinities ranging from 4 to 800nM (Carayannopoulos et al., 2002a; O’Callaghan et al., 2001; 
Li et al., 2001). Both chains of the NKG2D homodimer contribute to the interaction with the 
different monomeric ligands, making contacts with either the ǂ1 or ǂ2 domain of the ligand. 
Thus, the symmetric, homodimeric NKG2D receptor binds asymmetric ligands, and the 
contribution of the individual NKG2D chains is unequal (Radaev et al., 2002; Mc Farland et 
al., 2003). It is surprising that mouse and human NKG2D, which are only 69% identical in 
their ectodomains, can recognize most ligands of the other species (Mc Farland et al., 2003). 
1.1 Expression of NKG2D receptor 
The NKG2D receptor is constitutively expressed on most innate immune effector cells of 
lymphoid origin, including NK cells, most TCR Ǆǅ T cells (Jamieson et al., 2002), and a large 
fraction of NKT cells (Jamieson et al., 2002; Gumperz et al., 2002). Functional NKG2D is also 
found on murine interferon producing killer dendritic cells (IKDC) which are of myeloid 
origin (Taieb et al., 2006) interferon producing killer dendritic cells (IKDC) which are of 
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myeloid origin (Taib et al., 2006; Chan et al., 2006). On adaptive immune system cells, 
NKG2D is constitutively expressed on all human CD8+ T cells and on activated and 
memory (but not on naive) CD8+ ǂß T cells in the mouse (Jamieson et al., 2002). NKG2D is 
not normally expressed on CD4+ T cells (Table 1).  
 
 Human Mouse 
NK cells 
TCRǂǃ T cells 
 
 
 
 
TCRǄǅ T cells 
 
NKT cells 
DC 
Macrophages 
All NK cells 
Naïve, activated and memory  
CD8+ T cells 
Subpopulation of Synovial and 
circulating CD4+ T cells in 
rheumatoid arthritis patients 
Most blood and IEL TCRǄǅ  
T cells 
ND 
ND 
ND 
All NK cells 
Activated and memory CD8+ T cells 
Not express on naïve CD8+ T cells 
Not express on CD4+ T cells 
 
 
25% of splenic TCRǄǅ T cells 
Large fraction of NKT cells 
 
IKDC subset 
Only mRNA  
Table 1. Pattern of NKG2D receptor expression in human and in mouse. IEL: intestinal 
intraepithelial lymphocytes. IKDC: interferon producing killer dendritic cells. ND: not 
determined. (Coudert and Held, 2006). 
1.2 Function of NKG2D receptor 
Human NKG2D signals exclusively via DAP-10, while mouse NKG2D associates with both 
DAP-10 and DAP-12. Upon NKG2D engagement, DAP-12 recruits ZAP-70 and Syk protein 
tyrosine kinases with the help of its immunoreceptor tyrosine-based activation motif (ITAM) 
(Lanier et al., 1998). It has been observed that mouse deficient for DAP-12 retained 
significant NKG2D-dependent NK cell mediated killing (Diefenbach et al., 2002a; Zompi et 
al., 2003). Moreover, NK cells from Syk/ZAP-70 deficient mouse also retained significant 
lytic activity. In contrast, DAP-10 lacks an ITAM but instead contains a YINM motif. Upon 
engagement of human NKG2D, the recruitment of the p85 subunit of phosphatidylinositol 
3- kinase (PI3-K) (Wu et al., 1999) and of Grb2 to DAP-10 occurs (Chang et al., 1999). Both 
p85 and Grb2 have to be recruited to DAP-10 for full calcium flux and cell-mediated 
cytotoxicity (Upshaw et al., 2006). The residual lytic activity observed in DAP-12 deficient 
mice was abrogated when pharmacological blockade of Src family kinases and PI3-K, which 
act down-stream of DAP-10, were used (Colucci et al., 2002), indicating that DAP-10 is 
crucial for NK cell cytotoxicity. The NKG2D/DAP-10 complex triggers granule release and 
cytotoxicity following NKG2D crosslinking in human NK cells (Billadeau et al., 2003). Thus, 
ITAM-independent, DAP-10- dependent signaling triggers NKG2D-dependent cytotoxic 
function in NK cells. 
Besides NK cells, NKG2D receptors are constitutively expressed in human CD8+ T cells and 
upon activation in mouse CD8+ T cells. Since T cells generally lack DAP-12 expression, 
NKG2D signaling occurs exclusively via DAP-10 in humans and in mice. In T cells, NKG2D 
serves as co-stimulatory and in some instances, as primary activation function. In CD8+ T 
cells NKG2D engagement enhances T cell activation rather than induces activation (Groh et 
al., 2001; Maasho et al., 2005). Prolonged exposure of T cells derived from human intestinal 
epithelium to high amounts of IL-15 changes NKG2D function and expression by up-
regulating DAP-10 (Roberts et al., 2001).  
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1.3 NKG2D ligands  
NKG2D ligands are structurally similar to MHC class I molecules. The number of NKG2D 
ligands currently known stands at seven both in humans and mice. In humans these ligands 
are grouped into two families: the MHC-class-I-polypeptide related sequence A (MICA) and 
MICB protein family and the other family including cytomegalovirus UL16-binding protein 
(ULBP; also known as RAET1 proteins) consisting of five members (ULBP1–ULBP4 and 
RAET1G) (Bahram et al., 1994; Chalupny et al., 2003; Bacon et al., 2004). NKG2D ligands are 
variable in both their amino acid sequence and domain structure. MICA, for example, only 
shares 20–25% sequence identity with ULBP molecules (Radosavljevic et al., 2002). In mice 
there are five retinoic acid early transcript 1 (RAE1) proteins and the minor 
histocompatibility protein H60 and MULT (Diefenbach et al., 2003).  
All ligands share an MHC-class-I-like ǂ1ǂ2 domain that binds to NKG2D. The MICA and 
MICB proteins also have an additional ǂ3 domain. The RAE1 proteins in mice and ULBP1, 
ULBP2 and ULBP3 in humans are glycosylphosphatidylinositol (GPI)- anchored receptors. 
By contrast, MICA, MICB, ULBP4, RAET1G, H60 and MULT1 possess transmembrane 
domains and cytoplasmic tails (Eagle and Trowsdale, 2007). The ULBP genes are clustered 
in the telomeric region of human chromosome 6; a corresponding region with NKG2D 
ligands is found on mouse chromosome 10. The MICA and MICB genes are localized within 
the human HLA locus on chromosome 6, which also harbors orthologous MHC class I 
related Rae genes (Radosavlievic et al., 2002). Some NKG2D ligands are polymorphic, over 
70 distinct alleles have been identified in MIC genes (Radosavljevic et al., 2002). Even 
though the number of NKG2D ligands in humans and mice are same, phylogenetic analysis 
shows that these ligands have almost certainly diversified independently from each other 
(Raulet et al., 2003). 
1.4 NKG2D ligand expression 
The expression of NKG2D ligands are induced by a wide variety of stimuli referred as 
“cellular stress”, which includes tumorigenesis (Gasser et al., 2005), infection by a variety of 
pathogens (Lodoen et al., 2006), classic cell-stress stimuli such as heat shock (Venkataraman 
et al., 2007) and, also, as a result of Toll-like receptor (TLR) signaling (Nedvetzki et al., 2007). 
The aberrant expression of NKG2D ligands has also been linked with autoimmune diseases, 
including rheumatoid arthritis, coeliac disease and autoimmune diabetes (Hue et al., 2004). 
Not much is know about the precise mechanisms that lead to upregulation of NKG2D 
ligands. In cancer, NKG2D ligand expression has been associated with activation of the 
DNA-damage response pathways by genotoxic stress (Gasser et al., 2005). The triggers for 
switching on of NKG2D-ligand expression during infection have not yet been well defined 
(Eagle and Trowsdale, 2007). 
1.5 NKG2D ligands and tumor 
A large fraction of tumor cells express NKG2D ligands constitutively. MICA/B expression is 
detected on many types of epithelial tumor cell lines of different tissue origins (Bauer et al., 
1999; Jinushi et al., 2003; Groh et al., 1999; Groh et al., 1998). In contrast, ULBPs are 
preferentially expressed on T cell leukemia cell lines (Pende et al., 2002) as well as on freshly 
isolated lymphoid leukemia cells. RAE-1 and H60 are up-regulated in skin treated with 
carcinogens (Girardi et al., 2001)  and are found on skin, renal and lung carcinoma cell lines 
(Girardi et al., 2001; Smyth et al., 2002). The murine NKG2D ligands H60 and RAE-1 are also 
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found on numerous hematopoietic tumor cell lines (Lowin-Kropf et al., 2002). In some cases, 
NKG2D ligand up-regulation has been observed to be associated with transformation, 
having both oncogene and tumor suppressor roles. Embryonic fibroblasts deficient for JunB 
show an enhanced expression of RAE-1є and MULT1. JunB exerts tumor suppressor activity 
through the negative regulation of c-jun function (Deng et al., 1993). The chronic activity of 
the DNA damage response pathways have also been implicated to be responsible for the 
constitutive expression of NKG2D ligands such as RAE-1, MULT1 in mouse lymphoid 
tumor cell lines (Gasser et al., 2005).  
1.6 MULT1 ligand 
Murine ULBP-like transcript 1 (MULT1) is a ligand of NKG2D receptor. NKG2D receptors 
present on the effector cells recognize and bind to MULT1 on target cells. The cDNA 
sequence of MULT1 consists of a full length open reading frame (ORF) of 1.1 Kb and 
encoding a protein with a molecular weight of 37.1 KD. MULT1 protein is a type I 
transmembrane protein with an N-terminal signal sequence of 25 aa, two class I MHC like ǂ 
domains (89 aa and 91 aa, respectively), a transmembrane domain 17 aa and a cytoplasmic 
domain of 109 aa. Compare to other NKG2D ligands MULT1 lacks ǂ3- like domain and the 
GPI trans amidation site (Diefenbach et al., 2003). 
MULT1 protein is a glycoprotein with two ectodomains containing four N-glycosylation 
sites and one O-glycosylation site. Sequence alignments of MULT1 with other known mouse 
NKG2D ligands such as H60, Rae1ß and other known human NKG2D ligands such as 
MICA, ULBP1 and MHC-1, reveals that MULT1 protein is distantly related to known 
NKG2D ligands, which are in turn distantly related to MHC class I proteins. The sequence 
identity of MULT1 with known human ligands like MICA and ULBP1, are 16.7% and 29.9% 
respectively, thus MULT1 is closely related to the members of human ULBP family 
(Diefenbach et al., 2003). 
1.6.1 Expression of MULT1 ligand 
MULT1 mRNA is detected in a wide variety of tissues such as thymus, spleen, lymph nodes, 
and to a lesser extent liver and heart, but is not detected in kidney or brain. However, 
surface expression of MULT1 is not detected in lymph node, liver or kidney cells, suggesting 
that MULT1 may be regulated post-transcriptionally (Diefenbach et al., 2003). 
MULT1 mRNA expression has been observed in multiple tumor cell lines like YAC-1, 
WEH17.1, A20, P815, S49.1, BW5147 and TRAMP-C1. In WEHI7.1, S49.1 and BW5147 T cell 
lymphomas, and the P815 mastocytoma, MULT1 is the only known NKG2D ligand 
expressed in the cells. Other cell lines such as A20 B cell lymphoma and TRAMP-C1 prostate 
carcinoma coexpress MULT1 and RAE1 ligands (Diefenbach et al., 2003). The finding that 
MULT1, like RAE1 and H60 family members, is expressed by multiple tumor cell lines 
suggests that MULT1 contributes to immune surveillance in tumors (Diefenbach et al., 
2002b). 
1.6.2 Function of MULT1 ligand 
High-level expression of NKG2D ligand on a tumor cell helps the tumor cell to overcome 
class 1-mediated inhibition of NK cells resulting in its cell lysis (Carayannopoulos et al., 
2002). Tumor cells expressing high levels of MULT1 are highly susceptible to NK mediated 
lysis and strongly induce IFN-Ǆ production in freshly isolated, as well as IL-2 expanded, NK 
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cells. MULT1 also induces the production of nitric oxide in activated macrophages. When 
ectopically expressed by tumor cells, MULT1 induces a very potent antitumor response in 
vivo resulting in strong rejection of the transduced tumor cells in syngeneic B6 mice. 
Interestingly, the MULT1-transduced tumor cells have been observed to prime the mice, 
rendering them immune to the tumor antigens of the parental tumor cell (Diefenbach et al., 
2003). Tumor cells expressing different NKG2D ligands such as MULT1, RAE1ß and/or H60 
can induce protective immunity against multiple tumor cell lines such as RMA, B16-BL6 and 
EL4 (Hayakawa et al., 2002).  
MULT1 protein has a KD  of 6 nM and Koff of ~0.006 S-1 which is several times lower than 
RAE1є and H60 (KD ~ 10-30 nM ). MULT1 has a t 1/2 of ~ 2 min, longer than either H60 (~ 20 
s) or RAE1 ǂ-ǅ (~ 5s). These results indicate that MULT1 binds NKG2D with the highest 
affinity of all known ligands and has a half life longer than all known NKG2D ligands 
(Carayannopoulos et al., 2002a). Thus, three distinct MHC class 1-like molecules in the 
mouse, H60, RAE1є and MULT1 bind NKG2D with high affinity despite low mutual 
sequence identity (<20%).  
Evolutionary advantage of selecting such a complicated receptor ligand system is two-fold. 
First, the functional consequences of NKG2D engagement are pleiotropic, involving T cell 
co-stimulation, NK cell activation, macrophage stimulation, and possibly regulation of fetal 
development (Diefenbach et al., 2000; Groh et al., 2001). Precise execution of these diverse 
functions requires multiple genes with distinct promoter/enhancer sequences, 
posttranslational controls, and even kinetics of binding. Second, microbes exert enormous 
selective pressure to diversify immune-related functions, albeit at differing rates (Klein et 
al., 1993; Khakoo et al., 2000). Recent evidence suggests that human CMV interferes with the 
NKG2D system using the UL16 gene product to bind ULBP1 and ULBP2 (Cosman et al., 
2001) also, mouse CMV gp40 downregulates H60 (Krmpotic et al., 2002). Pathogen-encoded 
factors such as these might have selected for NKG2D-binding partners which retain receptor 
specificity but lack susceptibility to interference or subversion (e.g., ULBP3, which does not 
bind to UL16), resulting in the current repertoire of dissimilar NKG2D ligands 
(Carayannopoulos et al., 2002). 
1.7 Escape mechanism by tumors 
Tumors have developed many distinct mechanisms that would allow them to escape the 
detection by NKG2D expressing effector cells. As cancer progresses, immune pressure on 
the tumor may lead to selection of cells devoid of NKG2D ligands. It has been observed in 
cancer patients that most primary tumors seem to express NKG2D ligands, whereas more 
advanced tumors and metastases express very low level ligand (Vetter et al., 2004; 
Raffaghello et al., 2005). This leads to selection of variants with low levels of NKG2D 
ligands. 
NKG2D ligand cleavage has been observed in some tumors. Metalloproteinases can cleave 
MICA/B off the cell surface of tumor cells (Doubrovina et al., 2003) reducing their cell 
surface levels and limiting recognition by NKG2D-expressing effector cells. In addition, 
soluble NKG2D ligands such as MICA in the serum, upon binding to NKG2D, induce the 
internalization and lysosomal degradation of the NKG2D receptor on CD8+ T cells and NK 
cells (Doubrovina et al., 2003; Jinushi et al., 2003), reducing the efficiency of NKG2D 
recognition.  
TGF-ß, a major immunosuppressive cytokine produced by tumor cells also decreases the 
surface expression of MICA, effecting tumor cell recognition by CD8+ T and NK cells (Friese 
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et al., 2004). In vitro experiments have shown that NK cells cultured in the presence of TGF-ß 
down-regulated NKG2D receptor expression (Lee et al., 2004). It has been reported that IFN-
Ǆ can render certain susceptible target cells resistant to NK cell responses in vitro and in vivo. 
This has been attributed to an up-regulation of MHC class I molecules, which are recognized 
by inhibitory NK cell receptors (Bui et al., 2006).  
Research has also shown that sustained NKG2D ligand encounters can promote NK cell 
dysfunction in vitro and in vivo. The enforced constitutive expression of NKG2D ligands 
such as RAE-1ß, RAE-1є and MICA as transgenes in mice impair NKG2D functions in vivo 
(Wiemann et al., 2005). This observed NKG2D dysfunction also raises the possibility that 
CD8+ T cells and human NK cells may similarly be susceptible to inactivation. 
1.8 NKG2D ligands diversity  
Even though NKG2D ligands are not functionally equivalent, their roles are redundant to 
some extent (Komatsu et al., 1999). The evolutionary advantage for the presence of diverse 
NKG2D ligands can be explained with 3 possible reasons: 1) escaping immune recognition, 
2) evading tumor responses and 3) tissue specific function (Eagle and Trowsdale, 2007). 
1.8.1 Escaping immune recognition 
In nature, both host and pathogen are under natural selection pressure to diversify and 
refine their defense strategies in response to improvements made by their competitor. It has 
been observed that viruses, such as human cytomegalovirus (HCMV), MCMV, Influenza A, 
and Epstein–Barr virus, induce NKG2D ligands in infected cells (Draghi et al., 2007; 
Pappworth et al., 2007). As an escape mechanism HCMV deploys immunoevasin proteins 
such as UL16 that can bind to MICB, ULBP1, ULBP2 and RAET1G and prevent the 
expression of NKG2D ligands, helping the virus to escape immune recognition (Cosman et 
al., 2001; Chalupny et al., 2003; Bacon et al., 2004). Since viruses have evolved mechanisms to 
evade immune system, the host responds by developing variants of NKG2D ligands by gene 
duplication and going beyond the reach of the virus (Zhou et al., 2005; Chalupny et al., 
2006).  
1.8.2 Evading tumor responses 
One of the main functions of NKG2D is to participate in antitumour immune response and 
immune surveillance (Diefenbach et al., 2001; Smyth et al., 2005). Tumors have evolved 
many mechanisms that would allow them to avoid NKG2D-mediated immune attack. Some 
of these mechanisms are shedding soluble NKG2D ligands like MIC from their cell surface 
or down regulating MICA expression, producing TGF-ǃ, effectively anergizing NKG2D-
mediated immune recognition, and switching off the expression of NKG2D ligands as they 
progress (Groh et al., 2002; Vetter et al., 2004). Possessing multiple NKG2D ligands under 
the control of different cancer-related stress-response would provide the host with a fail-safe 
alert mechanism. Since expression of an individual NKG2D ligand may be lost as part of a 
cancer immunoediting process, the advantage of having more than one NKG2D ligand is 
that it would be much more difficult for the cancer to switch off multiple NKG2D ligands at 
once and help a host in detecting tumors (Eagle and Trowsdale, 2007). 
1.8.3 Tissue specific functions 
In humans, MICA and RAET1G proteins are expressed constitutively in the polarized 
epithelial-cell layer of the gut where they are likely to come in contact with pathogens (Groh 
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et al., 1996). MICA and ULBP1–ULBP3 are expressed by normal airway epithelial cells 
(Borchers et al., 2006). RAE1 transcripts were reported in mouse embryonic tissues such as 
embryonic brain (Nomura et al., 1996). MICA has a specialized role in the gut, whereas 
ULBP4 may have a related but equally specialized role in the skin (Groh et al., 1996).  
NKG2D ligands, like RAE-1 or MICA/B are not expressed in most tissues in healthy adult 
mice and humans (Nomura et al., 1996; Groh et al., 1996). ULBP1-3 mRNA is expressed in 
various healthy tissues (Cosman et al., 2001) and ULBP4 mRNA expression is detected in the 
skin (Jan Chalupny et al., 2003). Likewise, MULT1 mRNA is expressed in a wide variety of 
tissues such as thymus, spleen, lymph node, liver and heart (Carayannopoulos et al., 2002b; 
Diefenbach et al., 2003). RAE-1ß and RAE-1ǅ mRNA expression is detected in the early 
embryos, particularly in the brain (Nomura et al., 2006). Bone marrow cells express low 
levels of RAE-1 and H60 but not MULT1 (Ogasawara et al., 2003). Some NKG2D ligands are 
constitutively expressed in a restricted number of normal cells, indicating that they may 
have evolved unique tissue-specific functions that are not necessarily relate to their role in 
immune surveillance. Hence, it seems that NKG2D-ligand diversity may have allowed for 
the evolution of individual ligands with functional specialties that are specific for different 
cell types and tissues (Eagle and Trowsdale, 2007). 
1.9 NKG2D dependent immunotherapy 
As NKG2D receptor recognizes ligands that are constitutively expressed on many 
transformed but not on most normal cells, this provides an opportunity for their use in 
immunotherapy of cancer. Many different therapeutic strategies are being developed using 
NKG2D receptor-ligand interactions (Coudert and Held, 2006). Chimeric anti-tumor 
mAb/NKG2D-ligand, with the antibody portion of the chimeric protein specific to tumor 
cell targeting, while the NKG2D ligand re-directs NKG2D-expressing effector cells to the 
site of tumor have been generated. An anti-CEA (carcinoembryonic antigen)/MICA chimera 
and H60/anti-CEA specifically bind CEA+ human tumor cells and enhanced the in vitro 
lysis by NK cells in a NKG2D-dependent manner (Zhou et al., 2005). NKG2D receptor fused 
to the cytoplasmic portion of CD3ζ has been expressed in splenic T cells. This chimeric 
NKG2D receptor/CD3ζ protein confers primary activation function to T cells in response to 
NKG2D ligand-bearing tumor cells in vitro and induces memory response to NKG2D 
ligand-negative tumor cells (Zhang et al., 2005).  
Cytokines, such as IL-21, IL-12 and IFN-ǂ, exert anti-tumor effects by up-regulating NKG2D 
cell surface expression have been used in some tumor models with positive results. Mice 
treated with IL-21 have been observed to reject tumors cells more efficiently than control 
mice. IL-21 up-regulated NK cell mediated NKG2D-dependent tumor cell lysis in vitro and 
the rejection of grafted tumor cells in vivo (Takaki et al., 2005). Similar results were observed 
with IL-12 and IFN-ǂ (Zhang et al., 2005). 
Irradiation or alkylating compounds commonly used in chemotherapy treatment of cancer 
activate the DNA damage response pathway and can induce the expression of NKG2D 
ligands in mouse and human cells. ULBP3 and MICA are up-regulated by transretinoic acid 
in patients with chronic B cell lymphocytic leukemia (B-CLL) (Poggi et al., 2004). These 
treatments rendered tumor cells susceptible to killing by autologous NKG2D expressing 
effector cells and can be used as part of the combination therapy regime with any of the 
above discussed approaches (Coudert and Held, 2006). 
NKG2D recognition of multiple stress-inducible host proteins is of considerable research 
interest since this system has potential to be manipulated for therapeutic purposes. Tumor 
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cells expressing NKG2D ligands have been shown to be susceptible to NK cell mediated 
lysis, to induce a very potent antitumor response, and to provide protective immunity in 
vivo (Carayannopoulos et al., 2002a; Carayannopoulos et al., 2002b; Diefenbach et al., 2003; 
Kotturi et al., 2008; Eagle and Trowsdale, 2007). NKG2D recognition system has potential as 
a promising entry point to induce and/or improve immune responses against cancer for the 
following reasons. First, NKG2D ligands are generally poorly and only transiently 
expressed on healthy tissues, while they are constitutively expressed at significant levels on 
tumor cells. Second, NKG2D ligands are expressed on a broad variety of tumor cells of 
distinct tissue origins. Third, in situations where NKG2D ligands are poorly expressed, it 
may be possible to enhance their expression using radiation and/or chemotherapies. Fourth, 
NKG2D is expressed on all NK cells and also on a substantial fraction of T lymphocytes, 
providing a large number of potential effector cells. Fifth, cytokines may be used to improve 
NKG2D function. Finally, NKG2D-mediated adoptive immunotherapy should, in principal, 
be applicable to all individuals as the NKG2D receptor is monomorphic (Coudert and Held, 
2006). 
A great deal has yet to be understood about the involvement of NKG2D ligands in disease. 
A lot is known about the function of MICA; however, investigation of the expression and 
function of other NKG2D ligands with transmembrane domains and cytoplasmic tails is 
needed. A better understanding of the differences in the functional properties of NKG2D 
ligands and the pathways that regulate NKG2D ligand expression could help us develop 
better therapeutic interventions that could induce NKG2D-mediated immune responses and 
more efficient therapeutic strategies in the future (Eagle and Trowsdale, 2007). 
1.10 Fas/CD95  
CD95/APO-1/Fas receptor is a member of the tumor necrosis factor (TNF) superfamily of 
receptors. Its main function in signaling is the induction of apoptosis (Schulze-Osthoff et al., 
1998). CD95/Fas receptor is expressed on various human cells, including myeloid cells, T 
lymphoblastoid cells, and diploid fibroblasts. Fas is a 48-kDa type I transmembrane receptor 
of 319 amino acids with a single transmembrane domain of 17 amino acids, an N-terminal 
cysteine-rich extracellular domain and a C-terminal cytoplasmic domain containing 145 
amino acids relatively abundant in charged amino acids. The cytoplasmic portion of Fas 
contains a domain called “death domain” of about 85 amino acids. The “death domain” is very 
crucial as it plays a role in transmitting the death signal from the cell’s surface to 
intracellular pathways and mediates signaling through protein–protein interactions 
(Nagata, 1997). The tertiary structure of the Fas death domain consists of six antiparallel, 
amphipathic ǂ helices. Helices ǂ1 and ǂ2 are centrally located and flanked on each side by 
ǂ3/ǂ4 and ǂ5/ǂ6. This leads to an unusual topology in which the loops connecting ǂ1/ǂ2 
and ǂ4/ǂ5 cross over each other. The presence of a high number of charged amino acids in 
the death domain is responsible for interactions between death domains (Mollinedo and 
Gajate, 2006). CD95 receptors are expressed on the surface of cells as preassociated 
homotrimers (Siegel et al., 2000). These interactions were found to be mediated by a domain 
in the N-terminus, within the first of the cysteine-rich domains called PLAD (preligand 
binding assembly domain) (Siegel et al., 2000). CD95 receptors only function as trimers 
(Kischkel et al., 1995). 
CD95 contains a protein–protein interaction domain in its cytoplasmic region termed the 
death domain (DD) (Peter et al., 1999). When the preassociated receptor is ligated, CD95 
becomes competent to form the death-inducing signaling complex (DISC). In the DISC, the 
www.intechopen.com
 Cancer Gene Therapy via NKG2D and FAS Pathways 251 
adaptor molecule Fas-associated DD containing protein (FADD) binds to CD95 through 
homotypic interaction of its DD with the DD of CD95 (Kischkel et al., 1995). In addition to 
its DD, FADD contains another protein–protein interaction domain at its N-terminus, 
termed the death effector domain (DED). This domain recruits caspases containing these 
DED domains to the DISC. Both the DD and DED enable proteins containing the same 
domains to interact with one another. FADD interacts with procaspase-8 through its DED 
(Boldin et al., 1996). Thus, activation of Fas results in receptor aggregation and formation of 
DISC (Kischkel et al., 1995), containing trimerized Fas, FADD and procaspase-8. The 
apoptotic caspases perform different roles. The effector caspases, which include caspases 3, 
7, and 6 are responsible for most of the cleavage of proteins characteristic of apoptosis and 
are responsible for cleavage of proteins which induce the major morphological changes 
observed during programmed cell death (Ernshaw et al., 1999). Caspase-8 is a main initiator 
caspase and transduces the first signals of apoptosis in CD95 signaling and is expressed as 
two isoforms, caspase-8/a and -8/b, which are both recruited to the activated CD95 receptor 
(Scaffidi et al., 1997). Two molecules (FADD and caspase-8) are the key components of the 
CD95 DISC. Once procaspase-8 associates with FADD, the high local concentration of 
procaspase-8 leads to its autoproteolytic cleavage and activation (Salvesan and Dixit, 1999). 
Following the autoproteolytic cleavage of the enzyme, caspase-8 is released from the DISC 
as an active heterotetramer (Peter and Krammer, 2003).  
1.11 Fas ligand (FasL) 
FasL belongs to the TNF family and can be found as a 40-kDa membrane-bound or a 26-kDa 
soluble protein (Nagata, 1997). Rat FasL has no signal sequence at the N-terminus, but has a 
domain of hydrophobic amino acids in the middle of the molecule, indication that it is a 
type 11 membrane protein with the COOH-terminal region outside the cell. Mouse and 
human FasL are 76.9% identical at the amino acid sequence level and are functionally 
interchangeable. A stretch of about 150 amino acids in the extracellular region of FasL show 
significant homology to the corresponding region of other members of the TNF family 
which includes TNF, lymphotoxin (LT), CD40 ligand, CD27 ligand, CD30 ligand and OX40 
ligand. A single FasL gene is located on human and mouse chromosome 1 in the 
neighborhood of the OX40 ligand gene. Fas/FasL system is the major regulator of apoptosis 
at the cell membrane in mammalian cells through a receptor/ligand interaction (Mollinedo 
and Gajate, 2006).  
1.11.1 Expression of fasL 
FasL has been found to be expressed on cells of the lymphoid/myeloid lineage, including 
activated T cells and natural killer (NK) cells, where it plays an important role in immune 
homeostasis, T cell and NK cell-mediated toxicity (Brunner et al., 2003). FasL is also found to 
be expressed in sites such as the eye (Griffith et al., 1995) and testis (Bellgrau et al., 1995) 
contributing to immune privilege by inducing apoptosis of infiltrating proinflammatory 
immunocytes (Houston and O’Connell, 2004). FasL expression has also been observed in a 
variety of tumor cells indicating a possibility that FasL could mediate immune privilege in 
human tumors by inducing apoptosis of anti-tumor lymphocytes and also, stimulate 
proliferation of tumor cells (Houston and O’Connell, 2004). Tumor expression of FasL was 
first demonstrated in the colon carcinoma cell line SW620, where it could induce apoptosis 
of Fas-sensitive lymphoid cells in vitro (O’Connell et al., 1996). A functional FasL expression 
www.intechopen.com
 Targets in Gene Therapy 252 
has also been reported on numerous tumors of varying origin including colon (Okada et al., 
2000), gastric (Zheng et al., 2003), lung (Niehans et al., 1997) carcinoma, and astrocytoma 
(Saas et al., 1997). Tumor cells expressing FasL demonstrated the ability to kill Fas-sensitive 
target cells when co-cultured in vitro. Apoptosis of tumor-infiltrating lymphocytes (TILs) 
has also been detected in situ within FasL-expressing human tumors such as esophageal 
carcinoma (Houston and O’Connell, 2004; Okada et al., 2000; Zheng et al., 2003; Niehans et 
al., 1997).  
FasL expression was found to be higher in metastatic tumors than in primary ones. In breast 
and cervical tumors, high FasL expression was significantly associated with lymph node 
metastases (Kase et al., 2003) whereas, stronger FasL expression was found in liver 
metastases of colon cancer relative to the primary tumor (Houston and O’Connell, 2004). 
1.11.2 Inhibition of apoptosis  
One of the hallmarks of cancer is resistance to apoptosis (Hanahan and Weinberg, 2000). 
Most cancer cells are relatively resistant to apoptosis mediated through Fas. Fas-mediated 
apoptosis can be inhibited at different points in the apoptotic signaling pathway. Cells may 
secrete soluble ‘decoy’ receptors, such as sFasL or DcR3, which can bind to FasL and inhibit 
FasL-induced apoptosis (Pitti et al., 1998). FADD-like interleukin-1ß-converting enzyme 
inhibitory protein (cFLIP) binds to the DISC and prevents the activation of caspase-8 (Irmler 
et al., 1997). Reduced expression of FADD (Tourneur et al., 2003) or caspase-8 (Fulda et al., 
2001) can also inhibit Fas signaling. IAPs present in the cytosol can bind to and inhibit 
caspases and upregulation of Bcl-2 or Bcl-xL can render type II cells resistant to Fas-
mediated apoptosis. Cytochrome c and inhibitor-of-apoptosis protein (IAP) can inhibit 
apoptosis (Igney and Krammer, 2002). Thus, because of their insensitivity to Fas-mediated 
apoptosis, tumor cells can express FasL without undergoing apoptosis (Houston et al., 
2003). It has been observed that resistance to Fas-mediated apoptosis protects tumor cells 
not only from tumor-expressed FasL but also from FasL expressed as a cytotoxic mediator 
by infiltrating anti-tumor T cells and NK cells (Houston and O’Connell, 2004). 
1.12 Immunotherapy 
Death receptors are members of the tumor necrosis factor (TNF) receptor gene superfamily, 
consisting of more than 20 proteins with a broad range of biological function, including 
regulation of cell death, survival, differentiation or immune regulation (Debatin and 
Krammer, 2004). Death receptors share regions of high homology including cysteine-rich 
extracellular domains and a cytoplasmic domain of about 80 amino acids called death 
domain (DD), which plays a crucial role in transmitting the death signal from the cells 
surface to intracellular signaling pathways (Mollinedo and Gajate, 2006). 
The death receptors which have potential to induce apoptosis are Fas, TNF receptor 1 
(TNFR1), TNF-related apoptosis-inducing ligand receptor 1 (TRAIL-R1), TRAIL-R2, death 
receptor 4 (DR4) and death receptor 5 (DR5). Due to their potential to induce apoptosis, 
ligands such as TNF, Fas ligand (FasL) and TRAIL are interesting candidates for antitumor 
therapy (Shankar and Srivastava, 2004; Mollinedo and Gajate, 2006). However, ligands of 
the TNF family and their cognate receptors have been found to play a key role in liver 
pathogenesis and have become a major challenge for the clinical application of death 
receptor-targeted therapy (Hohenberger and Tunn, 2003; Ogasawara et al., 1993; Nesterov et 
al., 2002).  
www.intechopen.com
 Cancer Gene Therapy via NKG2D and FAS Pathways 253 
Conventional chemotherapy is based on the perception that malignant cells have 
uncontrolled proliferation. The rather modest impact of antiproliferative drugs in the clinic 
is not surprising since many tumors have a low growth capacity. In addition, exposure of 
normal tissues that have a high rate of cellular proliferation, such as the bone marrow, the 
gastrointestinal epithelial cells and the cells of the hair follicles, to anti-proliferative drugs 
leads to major toxicities. The effectiveness of anticancer drugs reflects the ability of tumor 
cells to detect and respond to the perturbation induced by the drug (Mashima and Tsuruo, 
2005). The failure of some tumor cells to die following drug treatment and their resistance to 
drugs is due to their resistance to apoptosis as tumors cells have defects in triggering their 
own death by apoptosis (Mollinedo and Gajate, 2006). If liver toxicity could be 
circumvented, Fas would be a worthy anticancer target due to its potent proapoptotic 
activity and widespread expression in tumor cells (Mollinedo and Gajate, 2006). 
1.13 Adenovirus and cancer gene therapy 
Different viral vectors like lentivirus, retrovirus, pox virus, herpes simplex virus-1, vaccinia 
virus, adeno-associated virus (AAV) and adenovirus have been used for experimental 
cancer gene therapy (Young et al., 2006). These viral vectors have been used individually 
and in combination with conventional therapies to treat cancers that are refractory to just 
conventional therapy (surgery, radiation, and chemotherapy). Of all the vectors used, 
adenoviruses are one of the most widely accepted viral agents for cancer gene therapy. The 
features of adenovirus that make them well suited for gene therapy are: its capacity for gene 
transfer (up to 7-8 Kb), in vivo stability, inability to integrate into host genome, ability to 
transduce dividing and non dividing cells, a well characterized genome and relative ease of 
production, purification and manipulation. From a clinical point of view, adenovirus is 
endemic in the human population and its natural pathogenicity is associated with mild 
respiratory infections, and therefore, manifests a well defined safety profile (Gomes and 
Tong, 2006; Young et al., 2006). 
Adenovirus was first isolated and cultured from human tonsils and adenoid tissues (Garnett 
et al., 2002). Currently, 51 human adenovirus serotypes have been identified and grouped 
into six subgroups (A-F) of which the most widely studied serotype are group C types 2 and 
5. Adenovirus is a non-enveloped icosohedral particle which carries a 36 Kb double 
stranded DNA genome. The capsid consists of three main components: hexon, penton and 
fiber. Hexon is the most abundant structural protein which appears to play a role in coating 
the virus. The pentameric structure called penton is known to mediate viral internalization. 
The fiber protrudes from the penton bases and appears to play a role in viral attachment to 
the cellular receptor namely coxsackie adenovirus receptor (CAR). Attachment via knob-
CAR interactions is followed by interactions between cellular integrins and an arginine-
glycine aspartic acid motif (RGD-motif) located at the penton base. This binding leads to the 
formation of endosomes, viral internalization, disassembly and the release of viral nucleic 
acid. Thereafter viral DNA is transported to the nucleus where the genes are expressed and 
viral replication occurs. The adenoviral genome can be divided into immediately early 
(E1A), early (E1B, E2, E3, E4), intermediate (IX, IVa2) and late genes. The early genes are 
expressed prior to viral replication consisting of mainly regulatory proteins that prepare the 
host cell for virus DNA replication and block antiviral mechanisms. The late viral genes 
encode for viral structural proteins. Importantly, E3 region encodes a variety of proteins 
involved in immune response evasion. Adenoviruses with deletions in E1 and/or E3 regions 
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have been developed to provide cloning sites for transgene insertion (Gomes and Tong, 
2006). 
1.14 Conditional replicative and oncolytic adenovirus for cancer therapy 
Research has shown that adenovirus can be safely used for gene delivery. Adenoviruses 
have been modified by replacing early genes, E1A and E1B or E3 with the gene of interest. 
Since the E1 unit is essential for viral replication, the recombinant vector is replicative 
defective and its replication requires helper functions provided by a packaging cell line with 
complementing E1 genes. However, these recombinant constructs have been useful mainly 
at local/ regional stage. Their therapeutic limitation has been the incomplete infection of 
tumor cells, transient expression of the transgene, and a lack of systemic efficacy. Recently, 
conditional replicative oncolytic adenoviruses have been shown to replicate and kill tumor 
cells without harming normal cells. The tumor specificity of these viruses has been 
manifested through the incorporation of tissue or tumor specific promoters that limit viral 
gene (Tong, 2006; Gomes and Tong, 2006). 
A recent study indicates that the use of adenoviral vectors for clinical gene therapy is 
widespread. As of July 2006, adenoviral vectors are used in 26% of the 1,192 current 
worldwide gene therapy clinical trials. Of the 301 clinical trials involving the use of Ad 
vectors, 76% are for the treatment of cancer followed by vascular disease and monogenic 
disorders at 14% and 7%, respectively (http://www.wiley.co.uk/ genetherapy /clinical/) 
(Campos and Barry. 2007). 
Adenoviral gene therapy approaches have shown promising results in clinical trials. 
Adenovirus mediated delivery of NTR (nitroreductase enzyme) from E. Coli by direct 
intratumoural injection in patients with primary or secondary liver cancer showed 
appropriate levels of NTR expression in tumor cells. The early clinical trial data of the 
NTR/CB1954 system in patients with liver cancer or prostate cancer are extremely 
encouraging (Palmer et al., 2004). Adenoviral delivery of TRAIL (tumor necrosis factor-
related apoptosis-inducing ligand) showed significant anti-tumor efficacy in animal models 
of aggressive primary and metastatic cancer (Ma et al., 2005). Clinical trials of a recombinant 
adenovirus expressing interleukin-12 (IL-12) in patients with advanced digestive tumors 
have produced evidence of antitumor effects (Sangro et al., 2004). 
2. Hypothesis and objectives  
2.1 Hypothesis 
A novel fusion protein consisting of MULT1 extracellular domain and Fas transmembrane 
and intracellular domains (MULT1E/FasTI) when expressed on a cell, would activate 
NKG2D expressing cells such as NK cells from its MULT1E extracellular region, upon 
binding of MULT1E to NKG2D receptor on NK cells. At the same time the engagement of 
the fusion protein with NKG2D receptor would send death signals into the cells that express 
the fusion protein and induce apoptosis of the cell (Fig.1).  
2.2 Objectives 
The work presented here is a two pronged approach of using a novel fusion protein 
consisting of MULT1 extracellular domain and Fas transmembrane and intracellular 
domains for cancer therapy. First, the construction and expression of MULT1E/FasTI fusion 
protein is examined. Second, in vitro and in vivo activity of the fusion protein is tested. 
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Finally, the adenoviral vector mediated delivery and in vivo therapeutic effect of the novel 
fusion protein is evaluated.  
 
 
Fig. 1. Schematic representation of proposed mechanism of novel fusion protein MULT1E 
/FasTI.  
3. Construction and evaluation of fusion protein MULT1E/FasTI 
3.1 Plasmid construction of pMULT1E/FasTI 
Thymus glands from 4-day old newborn C57BL/6J mice were removed and stored in liquid 
nitrogen. The glands were homogenized using a tissue homogenizer and total RNA was 
extracted using TRIzol reagent (Invitrogen, Carlsbad, CA). Primers were designed for 
amplification of the extracellular domain of MULT1 (Genebank accession # NM_029975) 
from 236bp to 868bp. The sequence of the 5’ primer is CCCAAGCTTATGGAGCTG 
ACTGCCAGTAACAAGGTCC and that of the 3’ primer is CGGGATCCGGTACTGAAA 
GATCCTGCAGGCTCCAG. At the 5’ end of the upstream primer, a HindIII enzyme site 
was created and at the 5’ end of downstream primer, a BamHI site was created. cDNA was 
synthesized from the extracted total RNA using an RT-PCR kit (Promega, Madison, WI). 
The fragment was excised and gel purified using a Qiagen gel purification kit (Valencia, 
CA). Double enzyme digestion was performed on the purified fragment using HindIII and 
BamHI. The enzyme digested fragment was then ligated into a pcDNA3.1 (+) vector 
(Invitrogen, CA). The full MULT1 cDNA sequence in the new vector, pMULT1E, was 
confirmed by DNA sequencing.  
The cDNA clone of the Fas receptor in pDNR-LIB (ATCC # 10088798) was purchased from 
American Type Collection Centre (ATCC, Manassas, VA). A pair of primers was designed 
for amplification of the transmembrane and intracellular domains of Fas from 524 bp to 
1013bp (Genebank accession# BC061160). The 5’ primer used was CGGGATCCCCC AGAA 
ATCGCCTATGGTTGTTGTTGACC and the 3’ primer was CGGAATTCTCACTCCAGACA 
TTGTCCTTCATTTTC. At the 5’ end of upstream primer, a BamHI enzyme site was created 
and at the 5’ end of downstream primer, an EcoRI enzyme site was created. DNA PCR was 
performed to amplify the Fas transmembrane and intracellular domains from pDNR-LIB. 
The gel purified fragment was treated with BamHI and EcoRI enzymes and ligated into the 
pcDNA3.1 (+)/Zeo vector to create pFasTI. The DNA sequence of the transmembrane and 
intracellular domains of Fas in vector pFasTI was confirmed by DNA sequencing.  
The cDNA fragment encoding the MULT1 extracellular domain was cut out from pMULT1E 
by HindIII and BamHI enzyme digestion and ligated into the pFasTI. The resulting vector 
was named pMULT1E/FasTI (Fig.2) and used for transfection. 
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Fig. 2. Construction of the MULT1E/FasTI plasmid.  
3.2 Expression of pMULT1E/FasTI 
Lung carcinoma TC-1 tumor cells were transfected with pMULT1E/FasTI. Three clones that 
were zeocin resistant were selected and labeled as L-5, L-7 and L-10. An in vitro cell growth 
study showed that all the clones grew at a similar rate as TC-1 cells. The cells of these clones 
were stained with anti-mouse MULT1 antibody and analyzed by fluorescence-activated cell 
sorting (FACS). The result showed that TC-1 cells and clone L-7 cells were negative, whereas 
clones L-5 and L-10 cells were strongly positive (Fig. 3). To confirm that MULT1E of the 
fusion protein can indeed bind to NKG2D, the cells were incubated with NKG2D/Fc, a 
recombinant fusion protein, and then stained with anti-mouse NKG2D antibody conjugated 
with fluorescein isothiocyanate (FITC). TC-1 cells and clone L-7 cells were dimly positive, 
whereas clones L-5 and L-10 cells were strongly positive (Fig. 4) with L-10 cells the 
strongest. The results indicate that clones L-5 and L-10 are MULT1E/FasTI-positive clones, 
whereas TC-1 and clone L-7 are negative for the fusion protein, but express some 
endogenous MULT1 protein. 
 
 
Fig. 3. FACS analysis of MULT1E/FasTI expression. A total of 5x105 cells of TC-1 and clones 
L5, L7 or L10 were stained with purified rat anti-mouse MULT1 antibody followed by goat 
anti-mouse IgG F(ab’)-FITC. The dashed lines are isotype controls.  
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Fig. 4. FACS analysis of MULT1E/FasTI expression. A total of 1x106 cells of TC-1 and clones 
L-5, L-7 or L-10 were first treated with NKG2D/Fc and then stained with anti-mouse 
NKG2D antibody conjugated with FITC. The cells were analyzed on FACS Calibur with 
CellQuest software. Dashed lines are controls without NKG2D/Fc incubation.  
3.3 Fusion protein MULT1E/FasTI induces apoptosis of cells 
To confirm the concept that when bound to its ligand NKG2D fusion protein 
MULT1E/FasTI can send death signals through its Fas portion into the cells, TC-1 cells and 
clones L-5, L-7, L-10 were treated with recombinant protein NKG2D/Fc and analyzed by 
Annexin V staining and caspase-3 activation assay. The treatment of NKG2D/Fc increased 
both Annexin V-positive cells and Annexin V/propidium iodide (PI) double-positive cells in 
clones L-5 and L-10, but not in TC-1 cells or clone L-7 (Fig. 5). After the NKG2D/Fc 
treatment, not only apoptotic cells (Annexin V-positive cells and Annexin V/PI double- 
positive cells), but also the necrotic cells (PI-positive/Annexin V-negative cells) in clone L-5 
and L-10 were significantly higher than those of TC-1 or clone L-7 (Fig. 6A and 6B). 
Similarly, caspase-3 activities in cells of clones L-5 and L-10 were significantly higher than 
those of TC-1 or clone L-7 (Fig. 6C). The treatment of NKG2D/Fc induced more apoptotic 
cells in clone L-10 than clone L-5 (Fig. 6A and 6C). 
3.4 Cells expressing MULT1E/FasTI activate NK cells 
It is critical to know whether fusion protein MULT1E/FasTI can activate NKG2D-expressing 
cells, such as NK cells. Cells from TC-1 or clones L-5, L-7 and L-10 were co-cultured with 
NK cells isolated from mouse spleen. Intracellular interferon-Ǆ (IFN- Ǆ) was detected by 
FACS analysis (Fig. 7A). The percentage of the NK cells that express IFN- Ǆ was significantly 
increased in wells that contained cells of clone L-5 or L-10 compared to those co-cultured 
with TC-1 (P<0.05). Although the percentage of NK cells expressing IFN-Ǆ in wells that 
contained cells of clone L-7 increased slightly compared to those co-cultured with TC-1 cells, 
it was not statistically significant (Fig. 7B). 
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Fig. 5. MULT1E/FasTI induces apoptosis. A total of 1x106 cells of TC-1 and clones L-5, L-7 
and L-10 were treated with 1 µg/ml NKG2D/Fc for 16 h. The cells were then analyzed for 
apoptosis and necrosis using Annexin V staining and PI. This figure is an example of the 
FACS data. 
 
 
 
 
 
 
Fig. 6. MULT1E/FasTI induces apoptosis. A total of 1x106 cells of TC-1 and clones L-5, L-7 
and L-10 were treated with 1 µg/ml NKG2D/Fc for 16 h. The cells were then analyzed for 
apoptosis and necrosis using Annexin V staining (A, B) or caspase-3 assay (C). The statistical 
analyses were conducted between the controls (open bars) and NKG2D/Fc-treated cells 
(solid bars) using two-way analysis of variance (ANOVA). The difference between 
NKG2D/Fc-treated L-5 cells and NKG2D/Fc-treated L-10 cells was also compared using 
Student’s t-test. *P<0.05; **P<0.01 and ***P<0.001. 
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Fig. 7. MULT1E/FasTI activates natural killer (NK) cells. A total of 1x106 cells of TC-1 and 
clones L-5, L-7 and L-10 were co-cultured with NK cells for 3 h. The cells were stained with 
anti-NK1.1-FITC and were then permeabilized and fixed, and stained with antimouse IFN-
Ǆ-PE. The cells were analyzed on FACS Calibur with CellQuest software. (A) represents an 
example of the FACS data and (B) is the summery of the data from three separate 
experiments. *P<0.05. 
3.5 In vivo antitumor effect of fusion protein MULT1E/FasTI 
The in vivo therapeutic effect of the fusion protein was evaluated in a subcutaneous tumor 
model as well as a pulmonary metastasis model. Two hundred thousand cells of TC-1 and 
clones L-5, L-7 and L-10 in 0.2 ml Hank’s balanced salt solution (HBSS) were injected 
subcutaneously into 6- to 8-week-old mice and tumor size was measured twice weekly with 
a caliper and tumor volume was calculated. The tumor growth of clone L-7 was slightly, but 
not significantly (P>0.05) slower when compared to that of TC-1 cells. At day 18, the growth 
of clones L-5 and L-10 was significantly slower (P<0.01, P<0.01) when compared to that of 
TC-1 cells. At day 24, the difference of tumor growth between TC-1 and clone L-10 was even 
more significant (P<0.001), whereas the difference of tumor growth between TC-1 and clone 
L-5 remained the same (P<0.01; Fig. 8). An even better antitumor effect of the fusion protein 
was observed in the pulmonary metastasis model. Four weeks after i.v. tumor cell injection, 
the mice were euthanized and lungs were excised (Fig. 9A). The total weight of the lungs 
with the tumors was measured (Fig. 9B) and the tumor nodules on the surface of the lungs 
were counted (Fig. 9C). The lungs isolated from mice injected with TC-1 cells were fully 
covered with tumors and weighed an average 0.82 g. All the four lungs have more than 200 
tumor nodules each. The lungs isolated from mice injected with clone L-7 cells are covered 
with many tumors as well and weighed averagely 0.48 g. There are 118, 89, 67, 125 tumor 
nodules on the lungs. The lungs isolated from mice injected with clones L-5 and L-10 were 
almost tumor free and weighed much less (0.15 and 0.14 g, respectively) than those of mice 
injected with either TC-1 cells or clone L-7 cells. The average weight of lungs from normal 
mice was 0.14 g. 
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Fig. 8. Subcutaneous tumor study. A total of 2x105 tumor cells of TC-1 or clones L-5, L-7 and 
L-10 in 0.2 ml HBSS were subcutaneously injected into C57BL/6J mice (four mice per 
group). Tumor growth was measured and presented as 1/2LW2. **P<0.01; ***P<0.001.    
 
 
Fig. 9. Pulmonary metastatic tumor study. A total of 2x105 tumor cells of TC-1 or clones L-5, 
L-7 and L-10 in 0.5 ml HBSS were i.v. injected into C57BL/6J mice (four mice per group). 
Four weeks after tumor cell injection, mice were killed and their lungs were dissected (A). 
The lungs were weighted (B) and the tumor nodules on the lungs were counted (C). *P<0.05; 
***P<0.001. 
3.6 Construction of adenoviral vectors 
In order to effectively deliver the fusion protein into cells, especially tumor cells, adenovirus 
vectors were chosen. Ad-MULT1E/FasTI, Ad-MULT1E and Ad-Lac-Z adenovirus were 
generated using the ViraPower Adenoviral Expression System (Invitrogen, Carlsbad, CA) 
according to the manufacturer’s instructions. The full-length cDNAs of MULT1E/FasTI or 
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MULT1E (Section 3.1) were cloned into the pCR ®8/GW/TOPO® vector.  The pCR 
®8/GW/TOPO®  vector with MULT1E/FasTI or MULT1E inserts  were used as entry clone 
vectors and transferred into the destination vector pAd/CMV/V5-DEST (Invitrogen, 
Carlsbad, CA) using the Gateway LR Clonase II enzyme mix according to the 
manufacturer’s directions (Invitrogen, Carlsbad, CA) to generate pAd/CMV/ 
MULT1E/FasTI/V5 and pAd/CMV/MULT1E/V5. The vectors were linearized with PacI 
enzyme and transfected into 293A cells using LipofectamineTM 2000 reagent as per 
manufacturer’s directions. The 293A cells were maintained in DMEM medium until a 
cytophathic effect was apparent 5–7 days post-transfection. Cells were collected and lysed 
by subjecting them to four freeze/thaw cycles. The cell debris was pelleted at 3000 x g for 15 
min and the supernatant was collected and stored at -80 °C as crude viral lysate.  Fifty 
microliters of crude viral lysate were added into each 293A cell culture dish and incubated 
for 2-3 days until an 80-100% cytophathic effect was observed. Two recombinant 
adenoviruses (Ad-MULT1E/FasTI and Ad-MULT1E) were harvested and purified using the 
Adeno-X TM virus Mini Purification Kit according to the manufacturer’s directions 
(Clontech, Mountain View, CA) and stored at -80 0C. Ad-Lac-Z was purchased directly from 
the manufacturer (Clontech) and amplified as per the above method.  Titers of Ad-
MULT1E/FasTI, Ad-MULT1E and Ad-Lac-Z stocks were determined using an Adeno-X TM 
Rapid Titer Kit as per manufacturer’s directions (Clontech). 
3.7 Adenoviral vector effectively delivers MULT1E/FasTI into cultured TC-1 cells 
Three adenoviral vectors were constructed: 1) Ad-MULT1E/FasTI containing the full fusion 
protein sequence of MULT1E extracellular domain and FasTI transmembrane and 
intracellular domains; 2) Ad-MULT1E containing only the MULT1E extracellular domain; 3) 
Ad-Lac-Z containing the Lac-Z gene as control adenoviral vector. The adenoviral vectors 
were linearized using Pac1 and transfected into 293A cells to generate adenoviral stocks. The 
titer of these adenoviral stocks are in the range of 1010 PFU/ml. 
TC-1 tumor cells were infected with Ad-MULT1E/FasTI viral particles with different 
multiplicities of infection (MOI): 500, 250, 100, 25, and 0 for 24 hours. The fusion gene 
expression was detected by RT-PCR (Fig. 10) and FACS analysis (Fig. 11). Both assays not 
only demonstrate the fusion gene expression in the infected cells, but also show a clear dose 
dependent expression manner.  
 
 
Fig. 10. RT-PCR analysis of AD-MULT1E/FasTI expression at different MOIs. RNAs were 
isolated from infected cells and RT-PCR was performed. Lanes  2, 4, 6, 8, 10 and 12 are 
1134bp RT-PCR product of total RNA from TC1 cells infected with Ad-MULT1E/ FasTI at 
MOIs 500, 250, 100, 50, 25 and 0, amplified with MULT1E forward and Fas reverse primers; 
Lanes 3, 5, 7, 9, 11 and 13 are ß-actin controls; and lanes 1 and 14 are 1 kb markers.  
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Fig. 11. FACS analyses of AD-MULT1E/FasTI expression at different MOIs. 5 x 105 TC1 cells 
were harvested from each group that were infected with Ad-MULT1E/FasTI at MOIs 500, 
250, 100, 50, 25, 0 and stained with purified rat anti-mouse MULT1 antibody followed by 
goat anti IgG F(ab’)-FITC. Dashed lines represent un-infected TC-1 cells. 
3.8 MULT1E/FasTI delivered by adenoviral vector induces apoptosis in TC-1 cells 
To confirm the activity of adenoviral vector delivered MULT1E/FasTI fusion protein in TC-
1 cells, recombinant NKG2D/Fc ligand was added to the infected cells. As MULT1E binds to 
its ligand NKG2D, the binding would send apoptotic signal through its FasTI region into 
TC-1 cells (Kotturi et al., 2008). When TC-1 cells were infected with 100 MOI of Ad-
MULT1E/FasTI and treated with NKG2D/Fc, their caspase 3 activity was significantly 
higher (p<0.001) than the cells that were also infected by Ad-MULT1E/FasTI but not treated 
with NKG2D/Fc. Ad-MULT1E or Ad-Lac-Z infection showed slightly increased caspase 3 
activity (p>0.05) compared with non-infected TC-1 cells (Fig. 12A). The caspase activity in 
Ad-MULT1E/FasTI infected and NKG2D treated TC-1 cells is adenoviral particle dose 
  
 
Fig. 12. Ad-MULT1E/FasTI infection induces apoptosis in vitro. A) TC-1 (5x105) cells were 
infected with Ad-MULT1E/FasTI, Ad-MULT1E and Ad-Lac-Z at 100 MOI. Twenty-four 
hour after infection, cells were treated with 1µg/ml NKG2D/Fc for 16 hrs.  The cells were 
then analyzed for apoptosis by caspase-3 assay. B) TC-1 (5x105) cells were infected with Ad-
MULT1E/FasTI at different MOIs: 500, 250, 100, 50, 25. Twenty-four hour after infection, 
cells were treated with 1µg/ml NKG2D/Fc for 16 hrs.  The cells were then analyzed for 
apoptosis by caspase-3 assay. The data represented are summaries of three separate 
experiments. *p< 0.05; **p< 0.01 and ***p< 0.001. 
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dependent: 500 MOI infection generated the highest caspase activity, while a 25 MOI 
infection did not show any increased caspase 3 activity compared with un-infected TC-1 
cells (Fig. 12B). 
3.9 Intratumor delivery of MULT1E/FasTI by adenoviral vector 
To observe the antitumor activity of MULT1E/FasTI delivered by adenoviral vector, 
subcutaneous TC-1 tumors were grown in C57BL/6J mice. When the tumor reached about a 
size of 40 mm3, Ad-MULT1E/FasTI, Ad-MULT1E or Ad-Lac-Z at a dose of 1x109 pfu/tumor 
in 0.05ml HBSS was injected into the tumors. Control mice received HBSS only. The 
injections were repeated every other day for 4 times. The size of the tumors was measured 
every two days. At day 22 after tumor cell injection, the mice were sacrificed and the tumors 
were collected and measured. Although tumors received Ad-MULT1E or Ad-Lac-Z grew 
slightly slower than tumors received only HBSS, tumors received Ad-MULT1E/FasTI 
showed the slowest growth rate (Fig. 13A). The end point tumor measurement confirmed 
the conclusion that Ad-MULT1E/FasTI treatment significantly slowed the tumor growth 
(P<0.01, Fig. 13B). 
 
 
Fig. 13. MULT1E/FasTI delivered by adenoviral vector inhibits in vivo tumor growth. TC-1 
cells (2 x 105) in 0.2ml HBSS were subcutaneously injected into flanks of C57BL/6J mice (n = 
6).  One week after tumor cell injection, various viral vectors at a dose of 1 x 109 pfu/tumor 
were intratumorally injected on every other day for a total of 4 injections. Control animals 
received injections of 50µl HBSS. Tumor growth was measured and presented as 1/2LW2 
(A). At the end of this experiment, the mice were sacrificed and tumors were harvested and 
measured (B). *P< 0.05 
3.10 MULT1E/FasTI delivered by adenoviral vector induces apoptosis in tumor 
In order to confirm that MULT1E/FasTI delivered by adenoviral vector slows tumor growth 
by inducing tumor cell to undergo apoptosis, two days after last adenoviral particle 
injection, some mice were i.v. injected with FLIVOTM in vivo apoptosis detection reagent. 
Thirty minutes later, the tumor tissues were collected and 7 µm frozen sections were 
produced. The slides were examined under fluorescent microscope and the green 
fluorescent cells were counted. The number of apoptotic cells in tumors receiving Ad-
MULT1E/FasTI is significantly higher than that of tumors receiving either Ad-MULT1E or 
Ad-Lac-Z. There are no significantly more apoptotic cells in tumors receiving Ad-MULT1E 
or Ad-Lac-Z when compared with tumors that received just HBSS (Fig. 14).  
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Fig. 14. MULT1E/FasTI delivered by adenoviral vector induces apoptosis in vivo. Two days 
after the last intratumor virus injection, 100µl of FLIVOTM in vivo apoptosis detection reagent 
(green) was injected into mice. Thirty minutes later, the mice were sacrificed and tumors 
collected. Frozen sections were made from the tumor tissues and examined under 
fluorescent microscope. The data presented are the sum of apoptotic cells from 12 random 
fields of each section. *** P < 0001   
4. Conclusion 
Tumor cells have developed multiple mechanisms to subvert and suppress immune 
responses by regulating cell-surface expression of Fas (Ivanov et al., 2003) and Fas ligand 
(Zheng et al., 2003) and shedding NKG2D ligands such as MULT1 (Raffaghello et al., 2004), 
resulting in escape from killing by infiltrating antitumor NK cells and T cells (Elsasser-Beile 
et al., 2003). As NKG2D ligand surface levels critically determine the susceptibility to 
NKG2D-mediated NK cell lysis, stable expression of NKG2D ligands on tumors would help 
increase NK cell lysis of tumors (Diefenbach and Raulet, 2001). In this study, we enhanced 
the cell-surface expression of MULT1, one of the mouse NKG2D ligands, by anchoring the 
extracellular domain of MULT1 on tumor cells using a transmembrane sequence of Fas. We 
also introduced the DD of Fas in the intracellular domain of the fusion protein 
MULT1E/FasTI, hoping to develop a bifunctional chimeric protein that can send an 
apoptosis signal to the tumor cells and at the same time activate NKG2D-expressing 
immune cells such as NK cells. 
We cloned the cDNA encoding the extracellular domain of MULT1 gene from thymus of 
new born mice and ligated it to the transmembrane and intracellular domains of mouse fas 
cDNA. The resulting fusion cDNA was inserted into a mammalian cell expressing vector 
under the control of CMV promoter.  The vector was then transfected into mouse TC-1 lung 
epithelial cancer cells, and stable cell lines expressing the fusion protein were established. 
The transcription of the novel fusion protein MULT1E/FasTI in the transfected cells was 
confirmed by RT–PCR and its expression was characterized by surface FACS analysis.   
One of the key features of the designed fusion protein is to send apoptosis signals into the 
cells expressing the fusion protein, upon binding to its ligand, NKG2D. Although we do not 
have direct evidence supporting that the binding of NKG2D can form DISC inside tumor 
cells, a clear apoptosis signal is sent to the cells as indicated by the increased caspase-3 
activity and increased Annexin V-positive cells after treatment with recombinant 
NKG2D/Fc. Our data shows that fusion protein MULT1E/FasTI, when expressed on cells, 
not only sends apoptotic signals into cells expressing it, but also activates immune cells that 
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express receptors for MULT1 like NK cells. When co-culutred with NK cells isolated from 
spleen, the fusion proteins expressing clones activated NK cells by producing IFN-Ǆ. 
This study shows that fusion protein MULT1E/FasTI has antitumor activity in vivo. We 
used a subcutaneous tumor model and a pulmonary metastatic tumor model in this study. 
In the subcutaneous tumor study, MULT1E/FasTI expressing clones formed smaller tumors 
compared to controls; and in the pulmonary metastasis study, mice completely rejected 
tumor cells expressing the fusion protein. We showed that the fusion protein had a much 
stronger antitumor effect in the pulmonary metastasis setting than in the subcutaneous 
setting. This is in agreement with a study demonstrating that NK cells are more effective 
against blood borne metastasis (Smyth et al., 2002). Previous studies have shown that tumor 
cells ectopically expressing NKG2D ligands such as MULT1 are potently rejected by 
NKG2D-expressing lymphocytes (Diefenbach et al., 2001). Our data shows that adding Fas 
to the MULT1 has a clear additional antitumor effect. 
A significant challenge facing cancer gene therapy is how to specifically deliver tumor-
killing genes into tumor cells efficiently. The recent development of adenovirus as gene 
delivery vectors opens a new window for cancer gene therapy (Cohen and Rudin, 2001; Ries 
and Korn, 2002). We used adenoviruses to deliver the fusion protein MULT1E/FasTI into 
tumor cells. The findings of this study demonstrate the therapeutic effect of adenovirus-
mediated gene therapy of novel fusion protein MULT1E/FasTI. The most encouraging 
finding from a preclinical viewpoint is that mice receiving treatment with Ad-
MULTE/FasTI showed more apoptosis in vivo, formed smaller tumors, and survived longer.   
NK cell function is regulated by a balance between activating and inhibiting receptor signals 
(Trinchieri, 1989; Diefenbach and Raulet, 2001). Several types of inhibitory NK cell receptors 
recognize MHC class I molecules on target cells and prevent NK cell cytotoxicity toward 
normal cells (Yokoyama et al., 1995). The expression of ligands for activating receptor on 
target cells tips the balance toward activation of NK cells and induces NK cell cytotoxicity 
by formation of NK cell lytic synapse. NK cell cytotoxicity involves the secretion of cytolytic 
effector molecules known as lytic granules. The induction of NK cell effector functions, such 
as cytotoxicity, requires the contact between the NK cell and its target cell. The events that 
occur following the interaction between a cytolytic cell and its target cell, and the formation 
of the NK cell lytic synapse can be divided into three main stages: 1) initiation stage, 2) 
effector stage, and 3) termination stage. Initiation stage includes adhesion and initial 
signaling for cell activation. Effector stage involves actin reorganization, receptor clustering, 
raft formation, polarization of the microtubule-organizing centre (MTOC) and lytic granule 
fusion with the plasma membrane. Termination stage includes a period of inactivity and 
detachment.  
Fas receptor activation can occur through different mechanisms. Binding of homotrimers of 
FasL to Fas can homotrimerize Fas receptor (Papoff et al., 1999; Siegel et al., 2000). A death 
domain-independent oligomerization domain in the extracellular region of the Fas, mapping 
to the N-terminal 49 amino acids, can also mediate homo- and heterooligomerization of the 
death receptor (Papoff et al., 1999). Apoptosis can be triggered in the absence of FasL by 
overexpression of the Fas cytoplasmic domain or Fas lacking the N-terminal 42 amino acids 
(Papoff et al., 1999), suggesting that the extracellular oligomerization domain of Fas is not 
required to initiate signaling and that self-association of the death domain is necessary and 
sufficient to induce cell death. The intracellular death domains of death receptors show a 
high tendency to self-associate, and when overexpressed by gene transfer in eukaryotic cells, 
trigger apoptotic signaling (Boldin et al., 1996). These findings indicate that the Fas receptor 
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plays an active role in its own clustering and that its oligomerization can be achieved in the 
absence of FasL. 
We hypothesize that, when NKG2D expressing cells such as NK cells come in contact with 
TC-1 cells expressing the MULT1E/FasTI fusion protein, an NK cell lytic synapse would be 
formed as a result of the receptor-ligand interaction between NK cells and fusion protein 
expressing target cells. At this NK cell lytic synapse, activated NKG2D receptors bind to 
MULT1 ligands, cluster together and form lipid rafts. Formation of lipid rafts consisting of 
receptor-ligand complexes would result in activation of NK cells and NK cell cytotoxicity 
with the release of lytic granules consisting of granzymes and IFN-Ǆ at the immunological 
synapse. Binding of NKG2D to the MULT1E region of the fusion protein causes clustering of 
the fusion protein, and through death domain interactions would trigger formation of 
microaggregates resulting in larger clusters of FasTI, formation of DISC, caspase-8 activation 
and apoptosis in cell. Hence, our fusion protein approach is a two pronged approach for 
activating NK cells as well as inducing apoptosis, when the fusion protein binds to NKG2D 
receptors. Even though we do not have evidence of the formation of lytic synapses with NK 
cells and DISC formation in fusion protein expressing cells, our IFN-Ǆ assay using NK cells 
and caspase-3 ELISA assay confirm the functionality of both MULT1E and FasTI regions in 
our fusion protein and the dual role of MULT1E/FasTI.               
In summary, a bi-functional chimeric protein containing the extracellular domain of MULT1 
and the transmembrane and intracellular domains of Fas is created. It may provide a 
potential avenue for new cancer therapies and supports further investigation of therapeutic 
strategies using other NKG2D ligands combined with Fas transmembrane and intracellular 
domains for treating cancer. When combined with adenovirus gene delivery vectors, 
especially the oncolytic adenovirus vectors, the fusion protein will provide a robust anti-
cancer agent. 
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